Zhejiang East Asia Pharmaceutical Co., Ltd.

Main study objectives To study the pharmacokinetics of the test formulation (T) Erdosteine Capsules (Specification: 0.3g, Zhejiang Dongya Pharmaceutical Co., Ltd.) and the reference formulation (R) Erdosteine Capsules (ERDOTIN®, Specification: 300mg, Edmond Pharma S.r.l.) in healthy adult subjects after a single oral administration in the fasting/fed state, and to evaluate the bioequivalence of the two formulations in the fasting/fed state. Secondary study objectives To evaluate the safety of the test formulation (T) Erdosteine Capsules and the reference formulation (R) Erdosteine Capsules (ERDOTIN®) in healthy subjects after oral administration in the fasting/fed state.

Main purpose: This study used Sumitomo Pharma Co., Ltd.'s certified mosapride citrate tablets [trade name: Gasmotin, specification: 5 mg (calculated as C21H25ClFN3O3?C6H8O7)] as the reference preparation. According to the relevant provisions of the bioequivalence test, the mosapride citrate tablets [specification: 5 mg (calculated as C21H25ClFN3O3?C6H8O7)] produced and provided by Zhejiang East Asia Pharmaceutical Co., Ltd. were used as the test preparation. The human bioequivalence test was conducted in the fasting/postprandial state to evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects. Secondary purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Primary objective: To investigate the in vivo pharmacokinetic characteristics of Tedizolid Phosphate Tablets (Specification: 200 mg) produced by Zhejiang East Asia Pharmaceutical Co., Ltd. and Tedizolid Phosphate Tablets (trade name: SIVEXTRO®; specification: 200 mg) produced by MSD Pharma (Singapore) Pte Ltd and manufactured by Patheon Inc. after a single oral dose in healthy Chinese subjects under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test preparation (specification: 200 mg) and reference preparation (trade name: SIVEXTRO®; specification: 200 mg) of Tedizolid Phosphate Tablets in healthy Chinese subjects after a single oral dose.